FDA clears Edesa’s IND to expand Phase 2 vitiligo trial to U.S. sites
Edesa Biotech announced that the U.S. Food and Drug Administration approved its IND for the Phase 2 study of EB06 in vitiligo, allowing patient enrollment in the United States. Recruitment is already under way in Canada and the first U.S. sites are slated to start enrolling next quarter. The double‑blind, placebo‑controlled trial will involve up to 80 adults with moderate‑to‑severe non‑segmental vitiligo, and the company expects topline results in the fourth quarter of 2027.
Why it matters
The clearance enables Edesa to broaden its trial footprint, potentially accelerating data read‑out and de‑risking its vitiligo program, which could affect the company’s valuation. The company also disclosed a Q3 2026 net loss of $5.4 million and cash of $10.3 million, indicating the financial resources available to fund the study.
Key facts
- 1The FDA cleared Edesa’s IND for the Phase 2 EB06 vitiligo study, permitting expansion to U.S. investigational sites. stocktitan.net
- 2Patient recruitment is ongoing in Canada and U.S. enrollment is expected to begin next quarter. stocktitan.net
- 3The trial will enroll up to 80 adults with moderate‑to‑severe non‑segmental vitiligo. stocktitan.net
- 4The primary efficacy measure is the average percentage change from baseline in the Facial Vitiligo Area Scoring Index at Week 28. stocktitan.net
- 5Topline data are anticipated in the fourth quarter of 2027. stocktitan.net
- 6Edesa reported a net loss of $5.4 million for the quarter ended June 30 2026 and held $10.3 million in cash and cash equivalents. rttnews.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.